Integrated BioTherapeutics, Inc. (IBT) is a pioneering biotechnology company at the forefront of discovering innovative vaccines and therapeutics for emerging infectious diseases. With a strong focus on bacterial and viral infections, IBT has developed a pipeline of promising product candidates.

In their bacterial program, IBT is dedicated to developing countermeasures against staphylococcal infections by targeting various toxins produced by S. Their flagship S. In their antiviral pipeline, IBT is focusing on unique Ebola and Marburg antibody therapeutics, vaccines for filoviruses and Nipah virus, and an extensive discovery pipeline for emerging viruses.

Moreover, IBT has developed a groundbreaking antibody engineering technology that combines toxin neutralization with effector functions by targeting anti-toxin antibodies to bacteria surfaces. In addition to their robust research, IBT operates a Contract Research Organization (CRO) called IBT Bioservices, providing cutting-edge infectious disease discovery capabilities and animal model testing services to industrial and academic clients. Located in Rockville, Maryland, IBT enjoys close collaborations with renowned United States Government agencies, biotechnology and pharmaceutical companies, as well as academic laboratories.

With its commitment to advancing infectious disease treatments and vaccines, Integrated BioTherapeutics is a driving force in biotechnology